key: cord-0709126-hbyxy4ln
authors: Liu, Lihong; Iketani, Sho; Guo, Yicheng; Chan, Jasper F-W.; Wang, Maple; Liu, Liyuan; Luo, Yang; Chu, Hin; Huang, Yiming; Nair, Manoj S.; Yu, Jian; Chik, Kenn K-H.; Yuen, Terrence T-T.; Yoon, Chaemin; To, Kelvin K-W.; Chen, Honglin; Yin, Michael T.; Sobieszczyk, Magdalena E.; Huang, Yaoxing; Wang, Harris H.; Sheng, Zizhang; Yuen, Kwok-Yung; Ho, David D.
title: Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2
date: 2021-12-21
journal: bioRxiv
DOI: 10.1101/2021.12.14.472719
sha: 3849abf55499d50335a9913cf713710e2457d72a
doc_id: 709126
cord_uid: hbyxy4ln

The Omicron (B.1.1.529) variant of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) was only recently detected in southern Africa, but its subsequent spread has been extensive, both regionally and globally1. It is expected to become dominant in the coming weeks2, probably due to enhanced transmissibility. A striking feature of this variant is the large number of spike mutations3 that pose a threat to the efficacy of current COVID-19 (coronavirus disease 2019) vaccines and antibody therapies4. This concern is amplified by the findings from our study. We found B.1.1.529 to be markedly resistant to neutralization by serum not only from convalescent patients, but also from individuals vaccinated with one of the four widely used COVID-19 vaccines. Even serum from persons vaccinated and boosted with mRNA-based vaccines exhibited substantially diminished neutralizing activity against B.1.1.529. By evaluating a panel of monoclonal antibodies to all known epitope clusters on the spike protein, we noted that the activity of 17 of the 19 antibodies tested were either abolished or impaired, including ones currently authorized or approved for use in patients. In addition, we also identified four new spike mutations (S371L, N440K, G446S, and Q493R) that confer greater antibody resistance to B.1.1.529. The Omicron variant presents a serious threat to many existing COVID-19 vaccines and therapies, compelling the development of new interventions that anticipate the evolutionary trajectory of SARS-CoV-2.

Influenza Data) also contain an additional RBD mutation, R346K, which is the defining mutation 122 for the Mu (B.1.621) variant 27 .

We therefore constructed another pseudovirus 123 (B.1.1.529+R346K) containing this mutation for additional testing using the same panel of mAbs 124 (Fig. 2d) . The overall findings resembled those already shown in resistance to NTD or RBD (class 1 or class 2) antibodies 4 but also revealed several mutations 139 that were previously not known to have functional importance to neutralization ( Fig. 3a and  140 Extended Data Fig. 4) . Q493R, previously shown to affect binding of CB6 and LY-CoV555 28 141 as well as polyclonal sera 29 , mediated resistance to CB6 (class 1) as well as to LY-CoV555 and 142 2-15 (class 2), findings that could be explained by the abolishment of hydrogen bonds due to the 143 long side chain of arginine and induced steric clashes with CDRH3 in these antibodies (Fig. 3b,  144 left panels). Both N440K and G446S mediated resistance to REGN10987 and 2-7 (class 3), 145

observations that could also be explained by steric hindrance (Fig. 3b, middle panels) . The 146 most striking and perhaps unexpected finding was that S371L broadly affected neutralization by 147 mAbs in all 4 RBD classes ( Fig. 3a and Extended Data Fig. 4) . While the precise mechanism 148 of this resistance is unknown, in silico modeling suggested two possibilities (Fig. 3b, The Omicron variant struck fear almost as soon as it was detected to be spreading in South 169

Africa. That this new variant would transmit more readily has come true in the ensuing weeks 2 . 170

The extensive mutations found in its spike protein raised concerns that the efficacy of current 171 COVID-19 vaccines and antibody therapies might be compromised. Indeed, in this study, sera 172 from convalescent patients (Fig. 1c) (Figs. 2c and 2d) . In addition to previously identified mutations that confer antibody 187 resistance 4 , we have uncovered four new spike mutations with functional consequences. Q493R 188 confers resistance to some class 1 and class 2 RBD mAbs; N440K and G446S confer resistance 189 to some class 3 RBD mAbs; and S371L confers global resistance to many RBD mAbs via 190 mechanisms that are not yet apparent. While performing these mAb studies, we also observed 191 that nearly all the currently authorized or approved mAb drugs are rendered weak or inactive by 192 B.1.1.529 (Figs. 2c and 3a) . In fact, the Omicron variant that contains R346K almost flattens 193 the antibody therapy landscape for COVID-19 ( Fig. 2d and 3a) . 

Fast gapped-read alignment with Bowtie 2

Integrative genomics viewer

Comparative tropism, replication kinetics, and cell damage profiling of 518

SARS-CoV-2 and SARS-CoV with implications for clinical manifestations

transmissibility, and laboratory studies of COVID-19: an observational study

Inference of macromolecular assemblies from crystalline 522 state

Pseudoviruses were produced in the vesicular stomatitis virus (VSV) background, in which the 432 native glycoprotein was replaced by that of SARS-CoV-2 and its variants, as previously 433 described 24 . Briefly, HEK293T cells were transfected with a spike expression construct with 434 polyethylenimine (PEI) (1 mg/mL) and cultured overnight at 37 °C under 5% CO 2 , and then 435 infected with VSV-G pseudotyped Δ G-luciferase (G*ΔG-luciferase, Kerafast) one day post-436